Swedish Orphan Biovitrum AB (publ)
BIOVF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1 | $6 | $6 | $7 |
| % Growth | -86.7% | -4.5% | -13.1% | – |
| Cost of Goods Sold | $1 | $1 | $2 | $2 |
| Gross Profit | -$0 | $5 | $5 | $6 |
| % Margin | -16.3% | 76.9% | 75.4% | 78.5% |
| R&D Expenses | $0 | $1 | $1 | $1 |
| G&A Expenses | $0 | $2 | $2 | $3 |
| SG&A Expenses | -$1 | $2 | $2 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $1 | $1 | $0 |
| Operating Expenses | -$0 | $4 | $4 | $4 |
| Operating Income | $0 | $1 | $1 | $2 |
| % Margin | 36.4% | 16.4% | 21% | 22.4% |
| Other Income/Exp. Net | -$1 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$0 | $1 | $1 | $1 |
| Tax Expense | -$0 | $0 | $0 | $0 |
| Net Income | -$0 | $1 | $1 | $1 |
| % Margin | -37.2% | 10.3% | 13.5% | 18.8% |
| EPS | -0.89 | 1.85 | 2.55 | 4.07 |
| % Growth | -148.1% | -27.5% | -37.3% | – |
| EPS Diluted | -0.89 | 1.83 | 2.52 | 4.03 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | $0 | $2 | $2 | $3 |
| % Margin | 47% | 30.8% | 35.5% | 34.9% |